Efficacy and safety of PD-1 inhibitors in recurrent or metastatic nasopharyngeal carcinoma patients after failure of platinum-containing regimens: a systematic review and meta-analysis

Abstract Objective There is a lack of standard salvage treatment options for recurrent or metastatic nasopharyngeal carcinoma (RM-NPC) that has failed platinum-containing regimens. Breakthroughs in immunotherapy have opened up new options for these patients. However, the efficacy and safety of immun...

書目詳細資料
發表在:	BMC Cancer
Main Authors:	Jian Luo, Wanying Xiao, Fengyang Hua, Yanqing Cao, Dongxia Wang, Xicheng Wang
格式:	Article
語言:	英语
出版:	BMC 2023-11-01
主題:	Recurrent or metastatic nasopharyngeal carcinoma Platinum-containing regimens PD-1 Efficacy Safety
在線閱讀:	https://doi.org/10.1186/s12885-023-11318-y

相似書籍

Are PD-1 inhibitors effective for recurrent/metastatic nasopharyngeal carcinoma? Meta-analysis and systematic review
由: Le Yan, et al.
出版: (2023-01-01)

Metastatic sites of baseline as predictors in recurrent or metastatic nasopharyngeal carinoma treated with PD-L1 inhibitor: a secondary analysis of multicenter, single-arm, phase II study (KL-A167)
由: Yuantai Li, et al.
出版: (2025-01-01)

Cost-effectiveness of pembrolizumab versus chemotherapy in patients with platinum-pretreated, recurrent or metastatic nasopharyngeal cancer
由: Jing Nie, et al.
出版: (2024-01-01)

Predictive and prognostic role of early apolipoprotein A‐I alteration in recurrent or metastatic nasopharyngeal carcinoma patients treated with anti‐PD‐1 therapy
由: Bi Jing Xiao, et al.
出版: (2023-08-01)

Advance in integrating platinum-based chemotherapy with radiotherapy for locally advanced nasopharyngeal carcinoma
由: Fubin Zhu, et al.
出版: (2023-09-01)

Prognostic value of early radiological response to first‐line platinum‐containing chemotherapy in patients with metastatic nasopharyngeal carcinoma
由: Guo‐Ying Liu, et al.
出版: (2020-02-01)

Efficacy and Safety of Re-Challenging PD-1 Inhibitors in Second-Line Treatment in Metastatic Nasopharyngeal Carcinoma Previously Treated with Chemotherapy and PD-1 Inhibitors
由: Bei W, et al.
出版: (2024-07-01)

Metastatic nasopharyngeal carcinoma: Outcome from Cancer Institute, Chennai
由: Arun Kumar, et al.
出版: (2020-01-01)

Toripalimab plus cetuximab combined with radiotherapy in a locally advanced platinum-based chemotherapy-insensitive nasopharyngeal carcinoma patient: a case report
由: Ying Piao, et al.
出版: (2024-05-01)

Prognostic analysis of peripheral blood inflammatory markers in 99 nasopharyngeal carcinoma patients with recurrence and metastasis
由: Weiguo Gu, et al.
出版: (2020-03-01)

Anlotinib as a third-line or further treatment for recurrent or metastatic nasopharyngeal carcinoma: a single-arm, phase 2 clinical trial
由: Yu Fang, et al.
出版: (2023-11-01)

Nimotuzumab combined with docetaxel and cisplatin as first-line treatment for patients with recurrent or metastatic nasopharyngeal carcinoma: a multicenter, phase 2 trial
由: Qihua Zou, et al.
出版: (2025-05-01)

The leadership of topotecan in the treatment of recurrent platinum-resistant ovarian cancer
由: K. E. Borisov
出版: (2014-07-01)

Pattern of Recurrence After Platinum-Containing Definitive Therapy and Efficacy of Salvage Treatment for Recurrence in Patients with Squamous Cell Carcinoma of the Head and Neck
由: Tetsuro Wakasugi, et al.
出版: (2022-07-01)

Association of lymphocyte subsets percentage with prognosis for recurrent or metastatic nasopharyngeal carcinoma patients receiving PD-L1 inhibitors
由: Jianming Diao, et al.
出版: (2025-03-01)

Spartalizumab in combination with platinum-doublet chemotherapy with or without canakinumab in patients with PD-L1-unselected, metastatic NSCLC
由: Armando Santoro, et al.
出版: (2024-10-01)

Camrelizumab plus famitinib in patients with recurrent or metastatic nasopharyngeal carcinoma treated with PD-1 blockade: data from a multicohort phase 2 studyResearch in context
由: Xi Ding, et al.
出版: (2023-07-01)

Efficacy and safety of first-line treatments for recurrent or metastatic nasopharyngeal carcinoma: a systematic review and network meta-analysis
由: Tongze Cai, et al.
出版: (2025-06-01)

Efficacy of Bevacizumab Combined with Paclitaxel and Platinum-Based Chemotherapy in Advanced Metastatic Cervical Cancer and Its Effect on T Lymphocyte Subsets and Tumor Markers
由: WANG Lijun, et al.
出版: (2023-10-01)

Expression of PD-L1 Molecule in Hypopharyngeal and Nasopharyngeal Carcinomas
由: Ahmed Roshdi Hamed Ahmed, et al.
出版: (2025-01-01)

Efficacy and safety of cadonilimab (PD-1/CTLA-4 bispecific) in combination with chemotherapy in anti-PD-1-resistant recurrent or metastatic nasopharyngeal carcinoma: a single-arm, open-label, phase 2 trial
由: Yaofei Jiang, et al.
出版: (2025-03-01)

Prognostic Impact of Advanced Lung Cancer Inflammation Index (ALI) on Immunotherapy Outcomes in Recurrent or Metastatic Nasopharyngeal Carcinoma: A Multicenter Post Hoc Analysis
由: Xu S, et al.
出版: (2025-10-01)

The prognostic significance of PD-L1 and PD-1 expression in patients with nasopharyngeal carcinoma: a systematic review and meta-analysis
由: Zi-Lu Huang, et al.
出版: (2019-05-01)

The goal of primary therapy in non-metastatic nasopharyngeal cancer should be radiological complete response
由: Mustafa Korkmaz, et al.
出版: (2022-07-01)

The efficiency of liposomal paclitaxel versus docetaxel in neoadjuvant chemotherapy with the TPF regimen for locally advanced nasopharyngeal carcinoma: a retrospective study
由: Zhi Yang, et al.
出版: (2024-10-01)

Concurrent chemoradiotherapy with S-1 versus platinum in the treatment of locoregionally advanced nasopharyngeal carcinoma: a multicenter, retrospective, propensity score-matched analysis
由: Chenbin Bian, et al.
出版: (2024-11-01)

LASSO-Cox model in the prognostic evaluation of radiochemotherapy efficacy for lymph node metastatic nasopharyngeal carcinoma
由: Simin Lu, et al.
出版: (2025-06-01)

Efficacy and safety of inetetamab-containing regimens in patients with HER2-positive metastatic breast cancer in first-line/second-line setting
由: Jian Zhang, et al.
出版: (2025-05-01)

Revisiting Treatment of Metastatic Urothelial Cancer: Where Do Cisplatin and Platinum Ineligibility Criteria Stand?
由: Mohammad Jad Moussa, et al.
出版: (2024-02-01)

Effects of locoregional radiotherapy in de novo metastatic nasopharyngeal carcinoma: A real-world study
由: Fujuan Zeng, et al.
出版: (2021-11-01)

Extending platinum-free interval in partially platinum-sensitive recurrent ovarian cancer by a non-platinum regimen: Its possible clinical significance
由: Yin-Ting Chuang, et al.
出版: (2012-09-01)

The efficacy and safety of apatinib plus capecitabine in platinum-refractory metastatic and/or recurrent nasopharyngeal carcinoma: a prospective, phase II trial
由: Lin-Quan Tang, et al.
出版: (2023-03-01)

PD-1 high expression predicts lower local disease control in stage IV M0 nasopharyngeal carcinoma
由: Feng Jiang, et al.
出版: (2019-05-01)

Preliminary evidence for endoscopic surgery combined with postoperative anti-PD-1 immunotherapy in advanced recurrent nasopharyngeal carcinoma
由: Haoyuan Xu, et al.
出版: (2023-12-01)

Cost-effectiveness analysis of first-line tislelizumab plus chemotherapy for recurrent or metastatic nasopharyngeal cancer
由: Zhengda Pei, et al.
出版: (2023-10-01)

Epstein–Barr Virus LMP1 Induces Soluble PD-L1 in Nasopharyngeal Carcinoma
由: Kina Kase, et al.
出版: (2021-03-01)

Anti-PD-1/PD-L1 for nasopharyngeal carcinoma: a comprehensive analysis of registered trials on ClinicalTrials.gov
由: Zelei Dai, et al.
出版: (2023-11-01)

Effects of oral maintenance chemotherapy and predictive value of circulating EBV DNA in metastatic nasopharyngeal carcinoma
由: Han Zhou, et al.
出版: (2020-04-01)

The use of BPaL containing regimen in the MDR/PreXDR TB treatments in Thailand
由: Piamlarp Sangsayunh, et al.
出版: (2024-02-01)

Combining interleukin 6 and EBV DNA levels predicts survival outcomes for patients with recurrent or metastatic nasopharyngeal carcinoma receiving chemoimmunotherapy
由: Ya Liu, et al.
出版: (2025-03-01)